| Drug Name |
Sugammadex sodium |
| Drug ID |
BADD_D02085 |
| Description |
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. |
| Indications and Usage |
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. |
| Marketing Status |
approved |
| ATC Code |
V03AB35 |
| DrugBank ID |
DB06206
|
| KEGG ID |
D05940
|
| MeSH ID |
D000077122
|
| PubChem ID |
6918584
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
53296-0119; 59651-409; 69037-0050; 76397-034; 62227-016; 69575-4041; 83137-0005; 51846-1056; 11722-068; 42973-233; 69766-065; 12860-0001; 63850-8099; 71796-003; 76397-033; 16436-0119; 65129-1418; 76397-030; 62147-0278; 82393-301 |
| UNII |
ERJ6X2MXV7
|
| Synonyms |
Sugammadex | Org 25969 | Sugammadex Sodium | 6-Perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt | Bridion |
